Mylan launching two new cost-saving HIV treatments in USA
Netherlands-incorporated Mylan (Nasdaq: MYL) on Friday announced that it will launch two new HIV treatments, Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) and Cimduo (efavirenz/lamivudine/tenofovir disoproxil fumarate).
Mylan anticipates introducing Symfi Loand Cimduo, both approved by the Food and Drug Administration last month, in the second quarter of this year.
These upcoming launches will extend Mylan's global antiretroviral (ARV) platform and help address the high cost of HIV treatment in the USA. Total spending for HIV medications in the USA exceeds $20 billion annually, and HIV is a top cost driver for many healthcare payers, such as Medicaid, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze